Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Eli Lilly and Rigel Pharmaceuticals announced a strategic collaboration to co-develop and commercialize R552, an investigational RIPK1 inhibitor, for…
Eli Lilly has agreed to pay Rigel Pharmaceuticals $125 million upfront plus up to $835 million in milestones for global rights to R552, Rigel's RIPK1 inhibitor…
Rigel Pharmaceuticals announced that Eli Lilly has elected to return all rights to R552 (ocadusertib) and the broader RIPK1 inhibitor program to Rigel under…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
Eli Lilly and Rigel entered a strategic collaboration to develop and commercialize RIPK1 inhibitors for inflammatory and autoimmune indications, plus CNS-penetrant RIPK1 candidates. Lilly paid $125M upfront and Rigel was eligible for up to $835M in development, regulatory and commercial milestones plus tiered royalties.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Rigel Pharmaceuticals, Inc. (this deal) | 2021 | $960M | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2021 deals · Eli Lilly and Company deals · Immunology deals